Seminars in arthritis and rheumatism最新文献

{"title":"Axial bone involvement in sarcoidosis has a good prognosis: Longitudinal study of a cohort of 48 patients","authors":"S Challal ,&nbsp;E Riviere ,&nbsp;B Lanseur ,&nbsp;F Jeny ,&nbsp;H Nunes ,&nbsp;M Soussan ,&nbsp;MC Boissier ,&nbsp;L Semerano ,&nbsp;N Saidenberg-Kermanac'h","doi":"10.1016/j.semarthrit.2025.152654","DOIUrl":"10.1016/j.semarthrit.2025.152654","url":null,"abstract":"<div><h3>Objectives</h3><div>Axial bone involvement in sarcoidosis is observed in approximately 25 % of patients on positron emission tomography (PET). Many of these lesions are asymptomatic, and their long-term outcomes are not well defined. This study aims to evaluate the prognosis of axial bone lesions in histologically confirmed sarcoidosis.</div></div><div><h3>Methods</h3><div>We assessed initial and follow-up MRI and PET from 48 patients diagnosed with axial bone sarcoidosis (135 MRI and 132 PET), with a mean follow-up duration of 33 and 44 months, respectively. Baseline and longitudinal associations between imaging results and patient variables were evaluated.</div></div><div><h3>Results</h3><div>MRI revealed predominantly nodular marrow replacement lesions, while PET identified multifocal bone involvement, with no corresponding bone lesions detected on CT in 80.8 % of cases. Compared to baseline imaging, serial MRI and PET showed significant reduction or resolution of bone lesions over time (MRI: <em>p</em> &lt; 0.01; PET: <em>p</em> &lt; 0.001). This was more frequently observed on PET (68.3 % of patients) than on MRI (19.5). During follow-up, bone pain improved significantly (<em>p</em> = 0.01), which was associated with favorable changes in both PET and MRI findings (<em>p</em> = 0.02 and <em>p</em> = 0.04, respectively). Seven patients had bone relapse. No epiduritis or soft-tissue infiltration was observed.</div></div><div><h3>Discussion</h3><div>This longitudinal evaluation over a 3-year period, combining clinical, radiological, and biochemical data, shows that sarcoidosis axial bone lesions have a favorable prognosis. Significant improvement was observed on both MRI and PET. The improvement in bone pain was associated with favorable imaging changes.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"71 ","pages":"Article 152654"},"PeriodicalIF":4.6,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143395429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transformative approaches for effective clinical trials to reduce the disease burden of osteoarthritis","authors":"Constance R. Chu ,&nbsp;Marc Hochberg ,&nbsp;Daniel White ,&nbsp;Scott Rodeo ,&nbsp;Johnny Huard ,&nbsp;Shane Shapiro ,&nbsp;Christian Lattermann ,&nbsp;Farshid Guilak","doi":"10.1016/j.semarthrit.2025.152652","DOIUrl":"10.1016/j.semarthrit.2025.152652","url":null,"abstract":"<div><div>Osteoarthritis (OA) is a leading cause of disability and morbidity that has eluded development of effective disease modifying drugs and therapies. While established OA in the form of symptomatic radiographic disease is a recognizable final common pathway, OA development encompasses a broad spectrum of pathological changes, susceptibilities, and etiological pathways that cannot be considered a single disease process. Beginning with preclinical disease where radiographs are normal, the concept of pre-osteoarthritis (pre-OA) offers a systems-based approach to OA prevention by targeting reduction of OA risk prior to the onset of definable OA. Early OA ensues when cellular, molecular, and joint tissue changes begin to overlap that of OA, a process that can begin before the onset of definitive symptoms or radiographic changes. A myriad of pathways and crossroads of pre-OA and early OA eventually leads to poorly irreversible symptomatic radiographic OA. With increasing recognition of pre-OA and early OA markers, pathways and subtypes, opportunities arise to address these new therapeutic targets. The current status of clinical trials in OA was identified as a critical barrier to progress by the 2022 National Institute of Arthritis, Musculoskeletal, and Skin Diseases (NIAMS) Roundtable on “Cartilage Preservation and Restoration in Knee Osteoarthritis: Challenges, Gaps, and Opportunities”. This manuscript summarizes the recommendations of the work group established from the Roundtable to address this issue. The work group recommends that clinical trial design and endpoints evolve to effectively evaluate new treatment approaches suitable for pre-osteoarthritis and early OA by different criteria than what has been set for symptomatic radiographic OA. While symptomatic improvement is the primary goal for palliation of irreversible established OA, important goals for treating earlier disease states include disease modification and prevention, with the potential to alter the natural history of progressive OA. Because symptoms may not correlate with structural changes in pre-OA and early OA, the primary outcomes in these trials need to match the intended mechanistic target and the therapeutic goal for the disease state being treated. The purpose of this manuscript is to transform the approach to clinical trials in OA by establishing a new benchmark of identifying critical outcomes that are appropriate for the joint disease states and subtypes of the target patient population, and the therapeutic or mechanistic target of the intervention being tested. By shifting the approach from using standardized outcomes based on established OA towards customizing clinical trials according to these principles, new precision medicine strategies to address the full spectrum of disease from pre-OA to OA can be more readily advanced into clinical practice.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"71 ","pages":"Article 152652"},"PeriodicalIF":4.6,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143438103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between cigarette smoking and radiographic progression in Psoriatic Arthritis","authors":"Fadi Kharouf ,&nbsp;Hernán Maldonado-Ficco ,&nbsp;Shangyi Gao ,&nbsp;Barry J Sheane ,&nbsp;Daniel Pereira ,&nbsp;Vinod Chandran ,&nbsp;Dafna D. Gladman","doi":"10.1016/j.semarthrit.2025.152653","DOIUrl":"10.1016/j.semarthrit.2025.152653","url":null,"abstract":"<div><h3>Objective</h3><div>The association between smoking and radiographic damage has been established in axial spondyloarthritis and rheumatoid arthritis, but not in psoriatic disease. We aimed to investigate this relationship in psoriatic arthritis (PsA).</div></div><div><h3>Methods</h3><div>We included patients with PsA from our observational cohort. Smoking status was assessed at each clinic visit and categorized as non-smoker, past smoker, or current smoker. We used linear mixed models to identify factors associated with the overall change in damage, as measured by the modified Steinbrocker score.</div></div><div><h3>Results</h3><div>Of 1736 patients included in the study, 952 (54.9 %) were males; the mean (standard deviation) age at baseline was 44.9 (13.3) years. 906 (52.2 %) patients were non-smokers, 211 (12.2 %) were past smokers, and 311 (17.9 %) were current smokers; 308 (17.7 %) patients had missing smoking data. The median [interquartile range] modified Steinbrocker score at baseline was 2.0 [0.0, 10.0]. In the multivariable linear mixed model, a longer duration between the first and last sets of radiographs, a higher baseline modified Steinbrocker score, and the use of conventional synthetic DMARDs were significantly associated with an increase in joint damage. Cigarette smoking—both current (estimate -0.18, 95 % confidence interval [CI] -0.94 to 0.58) and past (estimate -0.67, 95 % CI -1.51 to 0.17)—showed no significant association with the change in modified Steinbrcoker score.</div></div><div><h3>Conclusion</h3><div>Cigarette smoking does not appear to be significantly associated with the progression of joint damage in PsA. Further studies are required to confirm our findings.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"71 ","pages":"Article 152653"},"PeriodicalIF":4.6,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143291152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rheumatoid arthritis-associated interstitial lung disease: Advancing the identification and management","authors":"Bryant R. England","doi":"10.1016/j.semarthrit.2024.152578","DOIUrl":"10.1016/j.semarthrit.2024.152578","url":null,"abstract":"<div><h3>Background</h3><div>Interstitial lung disease (ILD) is an extra-articular manifestation of rheumatoid arthritis (RA) that causes substantial morbidity and mortality. Effective, evidence-based strategies to screen for, and manage, RA-ILD are lacking.</div></div><div><h3>Objectives</h3><div>Highlight recent research advances in, and further opportunities to improve, the identification and management of RA-ILD.</div></div><div><h3>Findings</h3><div>The goals of RA-ILD screening are early disease detection while avoiding unnecessary testing. Such an approach requires the ability to accurate risk stratify RA patients. With only a few recognized clinical risk factors for RA-ILD, a growing body of evidence on peripheral biomarkers for RA-ILD appears well suited to support a precision medicine approach. There is a paucity of evidence to guide management after RA-ILD diagnosis. While initial trials of antifibrotics have been conducted in RA-ILD and show the potential to slow the rate of pulmonary function decline, there have been no randomized trials of immunomodulatory therapies in RA-ILD. Supporting such trials, and addressing the barriers to conducting them, is a high priority.</div></div><div><h3>Conclusion</h3><div>Robust characterization of peripheral biomarkers in large, RA populations is essential to inform a precision medicine approach to RA-ILD identification. Randomized trials of treatments and treatment strategies that consider the systemic nature of RA-ILD are necessary to inform evidence-based RA-ILD treatment.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"70 ","pages":"Article 152578"},"PeriodicalIF":4.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142639709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rheumatoid arthritis prevention: We need to identify new targets for “NextGen” therapeutic trials","authors":"V. Michael Holers","doi":"10.1016/j.semarthrit.2024.152577","DOIUrl":"10.1016/j.semarthrit.2024.152577","url":null,"abstract":"<div><div>None</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"70 ","pages":"Article 152577"},"PeriodicalIF":4.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Defining a personalized treatment approach to rheumatoid arthritis: Using genetic markers of TNFi response","authors":"M. Elaine Husni ,&nbsp;Jean Lin ,&nbsp;Judy Zhang ,&nbsp;Unnikrishnan M. Chandrasekharan","doi":"10.1016/j.semarthrit.2024.152579","DOIUrl":"10.1016/j.semarthrit.2024.152579","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"70 ","pages":"Article 152579"},"PeriodicalIF":4.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Veterans Affairs Rheumatoid Arthritis Registry: A unique population in rheumatoid arthritis research","authors":"Ted R. Mikuls ,&nbsp;Joshua F. Baker ,&nbsp;Grant W. Cannon ,&nbsp;Bryant R. England ,&nbsp;Gail Kerr ,&nbsp;Andreas Reimold","doi":"10.1016/j.semarthrit.2024.152580","DOIUrl":"10.1016/j.semarthrit.2024.152580","url":null,"abstract":"<div><h3>Background</h3><div>As the largest integrated healthcare system in the U.S., the Veterans Affairs (VA) provides a unique context for the conduct of clinical and clinical-translational research in rheumatoid arthritis (RA).</div></div><div><h3>Objectives</h3><div>To review attributes of the VA Rheumatoid Arthritis Registry (RA) and highlight its research contributions.</div></div><div><h3>Findings</h3><div>With &gt;3,600 participants enrolled from 19 VA medical centers across the U.S., VARA includes longitudinally collected clinical data and a central biorepository that includes serum, plasma, and DNA collected at enrollment. VARA research capacity is enhanced via active linkages with internal data including the VA's Corporate Data Warehouse and elements captured during oncology care. This capacity is further enabled via active linkages with the National Death Index and Centers for Medicare &amp; Medicaid Services (CMS) data.</div></div><div><h3>Conclusion</h3><div>As a highly unique study population with comprehensive data annotation available to researchers, VARA is poised to continue address impactful questions in RA for years to come.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"70 ","pages":"Article 152580"},"PeriodicalIF":4.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142695910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychometric properties of patient-reported outcomes measurement information system (PROMIS) fixed short forms in Juvenile Myositis","authors":"Kaveh Ardalan ,&nbsp;Mariana C. Marques ,&nbsp;David Cella ,&nbsp;Megan L. Curran ,&nbsp;Elizabeth L. Gray ,&nbsp;Jungwha Lee ,&nbsp;Kyle J. Fahey ,&nbsp;Madison L. Wolfe ,&nbsp;Lauren M. Pachman ,&nbsp;Rowland W. Chang","doi":"10.1016/j.semarthrit.2025.152649","DOIUrl":"10.1016/j.semarthrit.2025.152649","url":null,"abstract":"<div><h3>Objectives</h3><div>Assess reliability and validity of Patient-Reported Outcomes Measurement Information System (PROMIS) pediatric self-report and parent-proxy report fixed short forms in juvenile myositis (JM).</div></div><div><h3>Methods</h3><div>Children with JM (8–17yo) and parents of 5–17 yo JM patients completed PROMIS measures (Physical Function, Pain Interference, Fatigue, Emotional Distress), PedsQL Generic Core scales and Rheumatology Module (PedsQL-GC/-RM). Internal consistency reliability was assessed via Cronbach's alpha. Patient-parent agreement was assessed via intraclass correlations (ICC). Concurrent and construct validity were assessed via Spearman's correlations between PROMIS versus PedsQL-GC/-RM and clinical/lab data respectively. Known-groups validity was assessed by comparing PROMIS T-scores between clinically distinct JM patients.</div></div><div><h3>Results</h3><div>We enrolled 75 JM participants, with 57 administered self-report and all 75 administered parent-proxy report measures per participant age. PROMIS measures were feasible (&gt;96% completion), with high internal consistency reliability (Cronbach's alpha &gt;0.8). Patient-parent assessments demonstrated moderate agreement (ICC &gt;0.5) for Mobility, Upper Extremity, and Fatigue domains, and smaller correlations (ICC 0.41–0.47) as expected for Pain Interference, Depressive Symptoms, and Anxiety. Concurrent validity was demonstrated by moderate correlation (Spearman's rho &gt;0.5) for all but 1 hypothesized relationships of PROMIS and PedsQL-GC/-RM domains. Although low disease activity and small sample size limited statistical power, construct validity and known-groups validity were demonstrable for multiple PROMIS pediatric self-report and parent-proxy report measures.</div></div><div><h3>Conclusion</h3><div>PROMIS measures show evidence of reliability and validity in JM. Child and parent reports differ sufficiently to suggest both should be collected. PROMIS measures can be considered for clinical and research use in JM.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"71 ","pages":"Article 152649"},"PeriodicalIF":4.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143376517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accrual of organ damage and one-year mortality in systemic sclerosis: A prospective observational study","authors":"Laura Cano-García ,&nbsp;Aimara García-Studer ,&nbsp;Sara Manrique-Arija ,&nbsp;Fernando Ortiz-Márquez ,&nbsp;Rocío Redondo-Rodríguez ,&nbsp;Paula Borregón-Garrido ,&nbsp;Natalia Mena-Vázquez ,&nbsp;Antonio Fernández-Nebro","doi":"10.1016/j.semarthrit.2024.152604","DOIUrl":"10.1016/j.semarthrit.2024.152604","url":null,"abstract":"<div><h3>Objective</h3><div>To determine cumulative organ damage in patients with systemic sclerosis (SSc) according to the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI), assess 1-year mortality risk, and identify associated factors.</div></div><div><h3>Methods</h3><div>A prospective, single-center study was conducted in a cohort of patients with SSc. A cross-sectional study and a 12-month longitudinal follow-up were carried out. The main outcomes were SCTC-DI and all-cause mortality at 12 months. Other variables included clinical-laboratory data, modified Rodnan Skin Score (mRSS), EuroQoL 5-D (EQ-5D), and Steinbrocker functional status. Multivariate models were used to study factors associated with SCTC-DI and mortality.</div></div><div><h3>Results</h3><div>The study population comprised 75 patients (97.3% females) with a mean age of 59.6 years. The median (IQR) of the SCTC-DI was 4(6), and only 4 (5.3%) patients had severe SCTC-DI (≥13). The factors associated with SCTC-DI were disease duration (β=0.276), mRSS (β=0.287), C-reactive protein (CRP) concentration (β=0.311), and EQ-5D (β= –0.207). After 1 year of follow-up, 4 patients had died. The factors associated with mortality at 12 months (OR [95% CI]) were baseline SCTC-DI ≥13 (44.5 [1.6–1237.9]; <em>p</em> = 0.025) and visual analog scale (VAS) of the EQ-5D (0.9 [0.8–0.9]; <em>p</em> = 0.018).</div></div><div><h3>Conclusions</h3><div>The SCTC DI can prove useful in clinical practice for assessing disease progression and short-term mortality risk. Cumulative damage was associated with disease duration, mRSS, CRP concentration, and a decline in EQ-5D, while the risk of death at 12 months was primarily associated with high SCTC-DI and low EQ-5D VAS. New studies are needed to improve assessment tools in patients with SSc.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"70 ","pages":"Article 152604"},"PeriodicalIF":4.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Value of ultrasound-assessed dactylitis in the early diagnosis of psoriatic arthritis","authors":"Otto Olivas-Vergara ,&nbsp;Lina Martínez-Estupiñán ,&nbsp;Fredeswinda Romero-Bueno ,&nbsp;Olga Sánchez-Pernaute ,&nbsp;Javier R. Godo ,&nbsp;María del Carmen Fariña-Sabaris ,&nbsp;Belén Ruffin-Vicente ,&nbsp;Agustina Criado-Alcazar ,&nbsp;Pablo E. Borges ,&nbsp;Sheila Recuero-Díaz ,&nbsp;Andrea Alvear-Torres ,&nbsp;Amalia Gil ,&nbsp;Antía García-Fernández ,&nbsp;Ana Elena Hoyo-Fernández ,&nbsp;M. Belén Ortega-Trompeta ,&nbsp;M. Isabel Sánchez-Barba-Izquierdo ,&nbsp;Gabriel Herrero-Beaumont ,&nbsp;Raquel Largo ,&nbsp;Esperanza Naredo","doi":"10.1016/j.semarthrit.2024.152612","DOIUrl":"10.1016/j.semarthrit.2024.152612","url":null,"abstract":"<div><h3>Purpose</h3><div>The primary objective of this prospective, longitudinal, observational, single-centre study was to evaluate the association between ultrasound-assessed lesions of dactylitis and the diagnosis of psoriatic arthritis (PsA) in patients with psoriasis (PsO) and hand arthralgia.</div></div><div><h3>Methods</h3><div>We included adult patients diagnosed with PsO with hand arthralgia, with or without other musculoskeletal complaints. They were clinically assessed at baseline, 6 and 12 months by a rheumatologist blinded to the ultrasound findings. At baseline, patients underwent a B-mode (BM) and power Doppler (PD) ultrasound assessment by other rheumatologist blinded to clinical data. The ultrasound evaluation included bilateral detection and scoring of synovitis (3 joints, 0-3), tenosynovitis (flexor tendons, 0-3), enthesitis (9 sites, 0-1), peri‑extensor tendon inflammation (PETI) (0-3), and subcutaneous tissue inflammation (SCTI) (0-3) in the 2nd-5th fingers.</div></div><div><h3>Results</h3><div>Seventy patients [44 women; mean (SD) age 51 (12.4) years] were included, of whom 64 completed the study. Of these, 15 (23.4 %) were diagnosed with PsA during the 12-month follow-up period. At finger level, the presence and amount of baseline BM and PD synovitis, BM tenosynovitis, BM and PD enthesitis, and BM and PD PETI were associated with PsA diagnosis (<em>p</em> &lt; .05). A predictive model including two variables, presence of PD synovitis and BM enthesitis, was found to predict PsA diagnosis (<em>χ</em>2 = 35.38; <em>p</em> &lt; .001) with an accuracy of 89.1 %, a sensitivity of 86.7 % and a specificity of 89.8 %.</div></div><div><h3>Conclusions</h3><div>Ultrasound-assessed lesions of dactylitis were associated with a diagnosis of PsA and the short-term development of PsA in patients with PsO and hand arthralgia.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"70 ","pages":"Article 152612"},"PeriodicalIF":4.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142897114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}